Antibody Humanization

Rx Biosciences offers reliable, rapid, and accurate antibody humanization by CDR grafting—a trusted technique in therapeutic antibody development. We begin by identifying the complementarity-determining regions (CDRs) from your antibody sequences. To ensure precision, we use proprietary algorithms that combine Kabat, IMGT, and Chothia methods.

After identifying the CDRs, we graft them onto human antibody frameworks. These frameworks are selected from our curated in-house database of over 10,000 human antibody sequences. Therefore, compatibility and stability are maximized. If necessary, we perform back-mutations to restore binding affinity and improve expression. As a result, we generate a panel of full-length, humanized antibodies that are ready for expression.

Moreover, our method preserves the binding characteristics of your original antibody while minimizing immunogenicity in human subjects. This makes it highly suitable for preclinical and clinical applications. Once the humanized versions are developed, they undergo careful evaluation for efficacy and performance.

Unlike generic approaches, our antibody humanization by CDR grafting process is tailored to meet your specific needs. It is particularly useful for researchers and biotech companies that require fast, precise, and scalable antibody engineering solutions.

In conclusion, partnering with Rx Biosciences ensures you receive a solution that is scientifically sound, efficient, and customizable to your project goals. Contact us today to accelerate your therapeutic pipeline with next-generation antibody technologies.